February 8th, 2006. SV40, genetic polymorphism and mesothelioma. pathological and epidemiological evidence
Discussion: Association of SV40 with human MM is suggested from laboratory observations but still lacks confirmation in well designed epidemiological studies. Other putative co-factors in MM occurrence are mutations in genes involved in repair of damage caused by asbestos, notably DNA-repair genes. Preliminary observations are available but epidemiological studies are needed to test this hypothesis.
July 1st, 2005. A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma
Our data indicate that human T lymphocyte samples carry DNA sequences coding for SV40 large T antigen at low prevalence, both in cancer cases and controls. Evidence of cytogenetic damage revealed as micronuclei frequency in mesothelioma cancer patients could be related to exogenous and endogenous cofactors besides asbestos exposure.
June 15th, 2005. SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure
Consequently, prolonged exposure to asbestos fibers progressively induces transformation of SV40-positive HMC. As a model of SV40/asbestos cocarcinogenesis, we propose that malignant mesothelioma originates from a subpopulation of transformed stem cells and that Akt signaling is a novel therapeutic target to overcome malignant mesothelioma resistance to conventional therapies.
Finally, a cooperative effect was observed between small molecule inhibitors of PI3-K and Onconase in the killing of malignant mesothelioma cells. Our results suggest that kinase screening of individual malignant mesotheliomas for endogenous levels of activated PI3-K/AKT may be predictive of the efficacy of Onconase and possibly other chemotherapeutic agents.
April 15th, 2005. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study
9). Our results suggest that SV40 increases the risk of MM among individuals exposed to asbestos.
April 7th, 2005. Epidemic of mesothelioma in Egypt
The use of EGFR inhibitors may have a role in the treatment of MM. Asbestos in Cairo is a silent killer and measures toward eliminating it entirely or at least strictly controlling human contact with this dangerous carcinogen have to be taken in order to combat the coming epidemic of mesothelioma in Egypt.
March 18th, 2005. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma
74. 1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.
January 26th, 2005. Pathogenesis of malignant pleural mesothelioma
Moreover, asbestos is still used in developing countries. The implication of other risk factors, especially SV40, supports a need for further research into MPM.
September 25th, 2004. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PC
Interpretation: Our data based on three independent experimental approaches do not support a significant role for SV40 in human mesotheliomas. The risk of false-positive results due to contamination by common laboratory plasmids containing SV40 sequences has been underestimated. Studies of SV40 based on PCR methods require careful primer design to reduce this risk. Relevance to Practice: This paper presents several lines of evidence against the proposed link between SV40 infection and human mesotheliomas. Studies reporting a high prevalence of SV40 DNA in human tumours have been based on molecular assays prone to false-positive results. Because SV40 appears unlikely to have a major role, if any, in human mesotheliomas, clinicians should continue to consider asbestos exposure as the most likely and most thoroughly established aetiological factor in individuals with this cancer.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Proteasome inhibitors
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the archives for the SV40 category.
